Referenze scientifiche

1. https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/
2. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. *Science*. 1990; 247:1465–1468. DOI: 10.1126/science.1690918
3. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. *Nat Rev Drug Discov*. 2018; 17:261–279. DOI: 10.1038/nrd.2017.243
4. Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. *Immunity*. 2005; 23:165–175. DOI: 10.1016/j.immuni.2005.06.008
5. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. *Nat Rev Mater*. 2021; 6:1078–1094. DOI: 10.1038/s41578-021-00358-0
6. Personalmente forse non entrerei qui nella discussione sull'efficacia, che fornirebbe alla recrudescente deriva NO VAX stimolo e materiale per attacchi che sposterebbero il focus della serie di articoli, che è tutt'altro. Magari sostituirei con una breve frase che riporti la dimostrata capacità dei vaccini a mRNA di indurre un'immunità umorale e, in alcuni casi, cellulo-mediata contro la proteina Spike. Negli articoli successivi (in particolare quello di Enzo e quello di Evelina, possiamo tornare magari a discutere l'efficacia clinica (sempre ricordandoci che il focus è un altro e quindi aprire polemiche sull'efficacia dei vaccini contro il COVID sarebbe inutile e controproducente).
7. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med*. 2020; 383:2603–2615. DOI: 10.1056/NEJMoa2034577
8. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med*. 2021; 384:403–416. DOI: 10.1056/NEJMoa2035389
9. Watson OJ, Barnsley G, Toor J, et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. *Lancet Infect Dis*. 2022;22:1293–1302. DOI: 10.1016/S1473-3099(22)00320-6
10. Irrgang P, Gerling J, Kocher K, et al. Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. *Sci Immunol*. 2023; 8:eade2798. DOI: 10.1126/sciimmunol.ade2798
11. Marchese AM, Fries L, Beyhaghi H, et al. Mechanisms and implications of IgG4 responses to SARS-CoV-2 and other repeatedly administered vaccines. *J Infect*. 2024; 89:106317. DOI: 10.1016/j.jinf.2024.106317
12. Wilson E, Goswami J, Baqui AH, et al. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. *N Engl J Med*. 2023; 389:2233–2244. DOI: 10.1056/NEJMoa2307079

13. Weber JS, Carlino MS, Khattak A, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. *Lancet*. 2024; 403:632–644. DOI: 10.1016/S0140-6736(23)02268-7
14. Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. *Nature*. 2023; 618:144–150. DOI: 10.1038/s41586-023-06063-y
15. https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/